Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Edward Hammond"'
Autor:
Gan-Lin Zhang, Cynthia A. Loomis, Haining Yang, Uri Barash, Chandra Goparaju, Edward Hammond, Neta Ilan, Arnon Nagler, Moshe Lapidot, Israel Vlodavsky, Sari Feld, Harvey I. Pass, Andre L. Moreira, Yaniv Zohar, Jin-Ping Li
BACKGROUND: Mammalian cells express a single functional heparanase, an endoglycosidase that cleaves heparan sulfate and thereby promotes tumor metastasis, angiogenesis, and inflammation. Malignant mesothelioma is highly aggressive and has a poor prog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b975a61bd90b7ad6147c7432bddefda1
https://europepmc.org/articles/PMC6186523/
https://europepmc.org/articles/PMC6186523/
Autor:
Argyris, Spyrou, Soumi, Kundu, Lulu, Haseeb, Di, Yu, Tommie, Olofsson, Keith, Dredge, Edward, Hammond, Uri, Barash, Israel, Vlodavsky, Karin, Forsberg-Nilsson
Publikováno v:
Molecular cancer therapeutics. 16(8)
Curative therapy for medulloblastoma and other pediatric embryonal brain tumors has improved, but the outcome still remains poor and current treatment causes long-term complications. Malignant brain tumors infiltrate the healthy brain tissue and, thu
Autor:
Anaud Gautam, Ligong Liu, Vito Ferro, Kat Davis, Edward Hammond, Elizabeth Copeman, Cai Ping Li, Keith Dredge, Ken D. Johnstone, Ian Bytheway, Tomislav Karoli
Publikováno v:
Seminars in Thrombosis and Hemostasis. 33:557-568
The heparan sulfate (HS) mimetic PI-88 is a promising inhibitor of tumor growth and metastasis expected to commence phase III clinical evaluation in 2007 as an adjuvant therapy for postresection hepatocellular carcinoma. Its anticancer properties are
Publikováno v:
PLoS ONE
PLoS ONE, Vol 7, Iss 12, p e52175 (2012)
PLoS ONE, Vol 7, Iss 12, p e52175 (2012)
PG545 is a clinically relevant heparan sulfate (HS) mimetic which, in addition to possessing anti-angiogenic properties, also acts as a heparanase inhibitor which may differentiate its mechanism(s) of action from approved angiogenesis inhibitors. The
Autor:
Ligong Liu, Tomislav Karoli, Kat Davis, Vitto Ferro, Cai Ping Li, Jessica Rowley, Laura Jane Sarimaa, Paul Handley, Ken D. Johnstone, Edward Hammond, Norbert Wimmer, Job Harenberg, Ian Bytheway, Keith Dredge
Publikováno v:
Journal of medicinal chemistry. 55(8)
Increasing the aglycone lipophilicity of a series of polysulfated oligosaccharide glycoside heparan sulfate (HS) mimetics via attachment of a steroid or long chain alkyl group resulted in compounds with significantly improved in vitro and ex vivo ant
Autor:
Ken D. Johnstone, Francis C. K. Chiu, Ligong Liu, David M. Shackleford, Tomislav Karoli, Keith Dredge, Elizabeth Copeman, Susan A. Charman, Cai Ping Li, William N. Charman, Job Harenberg, Ian Bytheway, Vito Ferro, Kat Davis, Thomas J. Gonda, Edward Hammond, Edmund Kostewicz
Publikováno v:
Journal of medicinal chemistry. 53(4)
A series of polysulfated penta- and tetrasaccharide glycosides containing α(13)/α(12)-linked mannose residues were synthesized as heparan sulfate (HS) mimetics and evaluated for their ability to inhibit angiogenesis. The compounds bound tightly to
Autor:
Ken D. Johnstone, Norbert Wimmer, Keith Dredge, Cai Ping Li, Vito Ferro, Kat Davis, Thomas J. Gonda, Ligong Liu, Anand Gautam, Ian Bytheway, Paul Handley, Edward Hammond
Publikováno v:
Investigational new drugs. 28(3)
Heparan sulfate mimetics, which we have called the PG500 series, have been developed to target the inhibition of both angiogenesis and heparanase activity. This series extends the technology underpinning PI-88, a mixture of highly sulfated oligosacch
Publikováno v:
Scopus-Elsevier
Heparanase is an endo-beta-glucuronidase that degrades the glycosaminoglycan heparan sulfate, a major component of the extracellular matrix and basement membranes, and has been implicated in such processes as inflammation, angiogenesis and metastasis